Hepatobiliary and pancreatic tumors represent a critical area of oncological research due to their aggressive nature, limited treatment options, and generally poor prognosis. Despite the application of traditional therapies, results have been modest, underlining the urgent need for more effective treatment strategies. Recent advances in the field of immuno-metabolic therapy, which leverage the immune system and metabolic pathways, have shown considerable promise in overcoming these challenges. This includes the development of immune checkpoint inhibitors, CAR T-cell therapies, and specific metabolic inhibitors. Nevertheless, significant obstacles such as tumor heterogeneity, immunosuppressive tumor microenvironments, and the intricate interplay between immune responses and metabolic pathways continue to complicate treatment outcomes.The objective of this Research Topic is to serve as a comprehensive platform for sharing cutting-edge research and clinical insights on immuno-metabolic therapies tailored to hepatobiliary and pancreatic malignancies. It seeks to explore the interplay between immunology and metabolism in tumor biology, and how this understanding can be leveraged to develop more effective treatment strategies. The focus will encompass a broad spectrum of topics, from preclinical studies to clinical trials, and from basic science discoveries to translational research.To gain deeper insights within this realm, this Research Topic encompasses a wide array of pertinent themes. We welcome articles addressing, but not limited to, the following:- Immuno-metabolic mechanisms in hepatobiliary and pancreatic tumors, examining immune cells, cytokines, and metabolic pathways.- Innovative immunotherapeutic strategies and their preclinical and clinical applications.- Targeting metabolic vulnerabilities in therapy.- The role of biomarkers in predicting responses to therapies.- Analysis of clinical trial designs and their outcomes, focusing on safety, efficacy, and long-term results.- Challenges in current treatments and future research directions, including resistance and toxicity.- Integration of immuno-metabolic therapies with standard treatment options.We welcome submissions in the form of Original Research, Reviews, and Perspectives.
Hepatobiliary and pancreatic tumors represent a critical area of oncological research due to their aggressive nature, limited treatment options, and generally poor prognosis. Despite the application of traditional therapies, results have been modest, underlining the urgent need for more effective treatment strategies. Recent advances in the field of immuno-metabolic therapy, which leverage the immune system and metabolic pathways, have shown considerable promise in overcoming these challenges. This includes the development of immune checkpoint inhibitors, CAR T-cell therapies, and specific metabolic inhibitors. Nevertheless, significant obstacles such as tumor heterogeneity, immunosuppressive tumor microenvironments, and the intricate interplay between immune responses and metabolic pathways continue to complicate treatment outcomes.The objective of this Research Topic is to serve as a comprehensive platform for sharing cutting-edge research and clinical insights on immuno-metabolic therapies tailored to hepatobiliary and pancreatic malignancies. It seeks to explore the interplay between immunology and metabolism in tumor biology, and how this understanding can be leveraged to develop more effective treatment strategies. The focus will encompass a broad spectrum of topics, from preclinical studies to clinical trials, and from basic science discoveries to translational research.To gain deeper insights within this realm, this Research Topic encompasses a wide array of pertinent themes. We welcome articles addressing, but not limited to, the following:- Immuno-metabolic mechanisms in hepatobiliary and pancreatic tumors, examining immune cells, cytokines, and metabolic pathways.- Innovative immunotherapeutic strategies and their preclinical and clinical applications.- Targeting metabolic vulnerabilities in therapy.- The role of biomarkers in predicting responses to therapies.- Analysis of clinical trial designs and their outcomes, focusing on safety, efficacy, and long-term results.- Challenges in current treatments and future research directions, including resistance and toxicity.- Integration of immuno-metabolic therapies with standard treatment options.We welcome submissions in the form of Original Research, Reviews, and Perspectives.
